Swedbank AB Has $26.22 Million Stake in Edwards Lifesciences Corporation $EW

Swedbank AB lowered its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 38.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 307,563 shares of the medical research company’s stock after selling 192,442 shares during the quarter. Swedbank AB’s holdings in Edwards Lifesciences were worth $26,220,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Edwards Lifesciences by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after acquiring an additional 365,581 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Edwards Lifesciences by 4.9% during the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after purchasing an additional 977,933 shares during the period. Bank of New York Mellon Corp increased its holdings in Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after acquiring an additional 1,423,365 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares during the last quarter. Finally, Holocene Advisors LP increased its holdings in Edwards Lifesciences by 0.9% in the 3rd quarter. Holocene Advisors LP now owns 4,746,694 shares of the medical research company’s stock worth $369,150,000 after acquiring an additional 42,717 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Trading Up 0.2%

NYSE EW opened at $85.93 on Tuesday. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $87.89. The stock has a market cap of $49.48 billion, a P/E ratio of 45.71, a P/E/G ratio of 2.15 and a beta of 0.87. The stock’s fifty day moving average price is $81.45 and its 200-day moving average price is $82.90. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same period in the prior year, the firm posted $0.64 earnings per share. The company’s quarterly revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 24,000 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total value of $2,012,160.00. Following the transaction, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,782,941.44. This represents a 53.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 106,684 shares of company stock valued at $8,811,739 over the last ninety days. 0.31% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

EW has been the subject of a number of recent analyst reports. Mizuho set a $95.00 target price on Edwards Lifesciences and gave the company an “outperform” rating in a report on Monday, April 13th. Wells Fargo & Company boosted their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Barclays reiterated an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Finally, Robert W. Baird boosted their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $95.65.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.